366 related articles for article (PubMed ID: 29247294)
1. rCBF and cognitive impairment changes assessed by SPECT and ADAS-cog in late-onset Alzheimer's disease after 18 months of treatment with the cholinesterase inhibitors donepezil or galantamine.
Shirayama Y; Takahashi M; Oda Y; Yoshino K; Sato K; Okubo T; Iyo M
Brain Imaging Behav; 2019 Feb; 13(1):75-86. PubMed ID: 29247294
[TBL] [Abstract][Full Text] [Related]
2. Relationships between cognitive impairment on ADAS-cog and regional cerebral blood flow using SPECT in late-onset Alzheimer's disease.
Takahashi M; Oda Y; Okubo T; Shirayama Y
J Neural Transm (Vienna); 2017 Sep; 124(9):1109-1121. PubMed ID: 28509077
[TBL] [Abstract][Full Text] [Related]
3. Characteristic deterioration of ADAS-Jcog subscale scores and correlations with regional cerebral blood flow reductions in Alzheimer's disease.
Yoshii F; Kawaguchi C; Kohara S; Shimizu M; Onaka H; Ryo M; Takahashi W
Neurol Sci; 2018 May; 39(5):909-918. PubMed ID: 29508099
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of treatment with donepezil hydrochloride and changes in regional cerebral blood flow in patients with Alzheimer's disease.
Yoshida T; Ha-Kawa S; Yoshimura M; Nobuhara K; Kinoshita T; Sawada S
Ann Nucl Med; 2007 Jul; 21(5):257-65. PubMed ID: 17634843
[TBL] [Abstract][Full Text] [Related]
5. Vascular risk factors and the relationships between cognitive impairment and hypoperfusion in late-onset Alzheimer's disease.
Takahashi M; Oda Y; Sato K; Shirayama Y
Acta Neuropsychiatr; 2018 Dec; 30(6):350-358. PubMed ID: 30132427
[TBL] [Abstract][Full Text] [Related]
6. Relationship between blood flow kinetics and severity of Alzheimer's disease: assessment of severity using a questionnaire-type examination, Alzheimer's disease assessment scale, cognitive sub-scale (ADAS(cog)).
Nebu A; Ikeda M; Fukuhara R; Shigenobu K; Maki N; Hokoishi K; Komori K; Yasuoka T; Tanabe H
Dement Geriatr Cogn Disord; 2001; 12(5):318-25. PubMed ID: 11455133
[TBL] [Abstract][Full Text] [Related]
7. Cholinergic enhancement increases regional cerebral blood flow to the posterior cingulate cortex in mild Alzheimer's disease.
Iizuka T; Kameyama M
Geriatr Gerontol Int; 2017 Jun; 17(6):951-958. PubMed ID: 27215917
[TBL] [Abstract][Full Text] [Related]
8. Predicting the neural effect of switching from donepezil to galantamine based on single-photon emission computed tomography findings in patients with Alzheimer's disease.
Oka M; Nakaaki S; Negi A; Miyata J; Nakagawa A; Hirono N; Mimura M
Psychogeriatrics; 2016 Mar; 16(2):121-34. PubMed ID: 26114924
[TBL] [Abstract][Full Text] [Related]
9. Clinical meaningfulness of Alzheimer's Disease Assessment Scale-Cognitive subscale change in relation to goal attainment in patients on cholinesterase inhibitors.
Rockwood K; Howlett SE; Hoffman D; Schindler R; Mitnitski A
Alzheimers Dement; 2017 Oct; 13(10):1098-1106. PubMed ID: 28341540
[TBL] [Abstract][Full Text] [Related]
10. SPECT follow-up study of cerebral blood flow changes during Donepezil therapy in patients with Alzheimer's disease.
Shimizu S; Hanyu H; Iwamoto T; Koizumi K; Abe K
J Neuroimaging; 2006 Jan; 16(1):16-23. PubMed ID: 16483272
[TBL] [Abstract][Full Text] [Related]
11. Effects of donepezil on the amplitude of low-frequency fluctuations in the brain of patients with Alzheimer's disease: evidence from resting-state functional magnetic resonance imaging.
Yang H; Zhang J; Cheng J
Neuroreport; 2021 Aug; 32(11):907-912. PubMed ID: 34029287
[TBL] [Abstract][Full Text] [Related]
12. Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months.
Blesa R; Davidson M; Kurz A; Reichman W; van Baelen B; Schwalen S
Dement Geriatr Cogn Disord; 2003; 15(2):79-87. PubMed ID: 12566596
[TBL] [Abstract][Full Text] [Related]
13. The Neuropsychological Correlates of Brain Perfusion and Gray Matter Volume in Alzheimer's Disease.
Tai H; Hirano S; Sakurai T; Nakano Y; Ishikawa A; Kojima K; Li H; Shimada H; Kashiwado K; Mukai H; Horikoshi T; Sugiyama A; Uno T; Kuwabara S
J Alzheimers Dis; 2020; 78(4):1639-1652. PubMed ID: 33185599
[TBL] [Abstract][Full Text] [Related]
14. Changes in regional cerebral blood flow and functional connectivity in the cholinergic pathway associated with cognitive performance in subjects with mild Alzheimer's disease after 12-week donepezil treatment.
Li W; Antuono PG; Xie C; Chen G; Jones JL; Ward BD; Franczak MB; Goveas JS; Li SJ
Neuroimage; 2012 Apr; 60(2):1083-91. PubMed ID: 22245641
[TBL] [Abstract][Full Text] [Related]
15. SPECT-identified neuroanatomical predictor of the cognitive effects of donepezil treatment in patients with Alzheimer's disease.
Hongo J; Nakaaki S; Shinagawa Y; Murata Y; Sato J; Tatsumi H; Tohyama J; Soma T; Iidaka T; Fukui T; Mimura M; Furukawa TA
Dement Geriatr Cogn Disord; 2008; 26(6):556-66. PubMed ID: 19066429
[TBL] [Abstract][Full Text] [Related]
16. Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months.
Rockwood K; Dai D; Mitnitski A
Int J Geriatr Psychiatry; 2008 Feb; 23(2):207-14. PubMed ID: 17621382
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of a high dosage of donepezil for Alzheimer's disease as examined by single-photon emission computed tomography imaging.
Kanaya K; Abe S; Sakai M; Fujii H; Koizumi K; Iwamoto T
Psychogeriatrics; 2012 Sep; 12(3):172-8. PubMed ID: 22994615
[TBL] [Abstract][Full Text] [Related]
18. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease.
Wilcock G; Howe I; Coles H; Lilienfeld S; Truyen L; Zhu Y; Bullock R; Kershaw P;
Drugs Aging; 2003; 20(10):777-89. PubMed ID: 12875613
[TBL] [Abstract][Full Text] [Related]
19. Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors.
Nobili F; Koulibaly M; Vitali P; Migneco O; Mariani G; Ebmeier K; Pupi A; Robert PH; Rodriguez G; Darcourt J
J Nucl Med; 2002 Aug; 43(8):983-90. PubMed ID: 12163621
[TBL] [Abstract][Full Text] [Related]
20. Effects of long-term Donepezil therapy on rCBF of Alzheimer's patients.
Nobili F; Vitali P; Canfora M; Girtler N; De Leo C; Mariani G; Pupi A; Rodriguez G
Clin Neurophysiol; 2002 Aug; 113(8):1241-8. PubMed ID: 12140003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
